Andera looks early for cancer immunotherapy
How Grey Wolf's A round helped Andera diversify its cancer immunotherapy portfolio
Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey Wolf, announced with the closing of a second tranche on Feb. 11.
The first £5 million ($6.5 million) tranche closed in 2018, one of three cancer immunotherapy investments Andera made that year. The others were late-stage buy-ins, as Andera led a $70 million series B for Crescendo Biologics Ltd. and a £65 million ($84.3 million) series B for Artios Pharma Ltd. (see “Andera Leads Crescendo’s $70M Series B” & “Artios Raises £65M Series B”)...